Ipamorelin / CJC-1295

What is Ipamorelin / CJC-1295?

Ipamorelin is a selective growth hormone releasing peptide (GHRP) — a pentapeptide that stimulates GH release by binding to the ghrelin receptor (GHSR) on the pituitary gland. Unlike older GHRPs (GHRP-2, GHRP-6), Ipamorelin is highly selective for GH release and does not significantly increase cortisol or prolactin — making it one of the cleanest GH secretagogues available.

CJC-1295 is a long-acting synthetic analog of GHRH (growth hormone releasing hormone). When formulated with DAC (Drug Affinity Complex), it has a half-life of approximately 6–8 days — providing sustained GHRH receptor stimulation that amplifies the pulsatile GH release triggered by Ipamorelin. The combination creates a synergistic effect: CJC-1295 primes the pituitary while Ipamorelin triggers the release.

The Ipamorelin/CJC-1295 combination is the most prescribed GH peptide stack in integrative and longevity medicine. It produces significant improvements in body composition, sleep quality, recovery, and overall vitality — with a safety profile that makes it suitable for long-term use under clinical supervision.

Synergistic GH stimulation through two pathways

Dual-Pathway GH Stimulation

CJC-1295 activates GHRH receptors (the same pathway as Sermorelin) while Ipamorelin activates ghrelin receptors — two distinct GH-stimulating pathways that work synergistically to produce a larger, more sustained GH pulse than either peptide alone.

Sustained GHRH Receptor Activation (CJC-1295)

The DAC formulation of CJC-1295 binds to albumin in the bloodstream, extending its half-life to 6–8 days. This provides continuous background GHRH receptor stimulation that amplifies the acute GH pulses triggered by Ipamorelin.

Selective GH Release (Ipamorelin)

Ipamorelin selectively stimulates GH release without significantly affecting cortisol, prolactin, or ACTH — avoiding the side effects associated with less selective GHRPs.

IGF-1 Elevation

The combined GH stimulation from both peptides produces sustained IGF-1 elevation — driving the anabolic, regenerative, and metabolic benefits of the protocol.

Sleep Architecture Enhancement

The GH pulse triggered by Ipamorelin/CJC-1295 at bedtime amplifies the natural nocturnal GH surge — deepening slow-wave sleep and improving overall sleep quality and recovery.

What patients report

—

Significant improvement in body composition — reduced fat, increased lean mass

—

Enhanced sleep quality and deeper, more restorative sleep

—

Faster recovery from exercise, injury, and physical stress

—

Improved energy, stamina, and physical performance

—

Support for bone density and connective tissue health

—

Improved skin quality, collagen density, and hair health

—

Enhanced cognitive clarity and mental sharpness

—

Support for libido and sexual function

—

Selective GH stimulation — minimal cortisol or prolactin elevation

Who may benefit from Ipamorelin / CJC-1295?

—

Adults seeking body composition improvement — fat loss and lean mass preservation

—

Individuals experiencing age-related decline in energy, recovery, or sleep quality

—

Athletes and active individuals seeking enhanced performance and recovery

—

Those with documented low IGF-1 levels

—

Patients in our Essential or Advanced Peptide Optimization programs

—

Individuals seeking anti-aging support through physiological GH restoration

—

Those who want the most widely studied and clinically used GH peptide combination

Frequently asked questions

Why is Ipamorelin/CJC-1295 considered the best GH peptide combination?

The combination is considered the gold standard because it stimulates GH through two complementary pathways simultaneously — producing a larger, more sustained GH pulse than either peptide alone. Ipamorelin's selectivity (minimal cortisol/prolactin elevation) and CJC-1295's long half-life make the combination both effective and well-tolerated for long-term use.

How does this compare to Sermorelin?

Both Sermorelin and CJC-1295 are GHRH analogs that stimulate GH through the same receptor. CJC-1295 has a significantly longer half-life (6–8 days vs. ~30 minutes for Sermorelin), which means less frequent dosing and more sustained receptor stimulation. The addition of Ipamorelin creates the dual-pathway synergy that Sermorelin alone cannot provide.

Will I experience water retention?

Mild, transient water retention is sometimes reported in the first few weeks as GH levels rise. This typically resolves as the body adapts. It is less pronounced with Ipamorelin/CJC-1295 than with direct GH administration. Staying well-hydrated and monitoring sodium intake can help minimize this effect.

How long before I see results?

Sleep quality improvements are often reported within 1–2 weeks. Energy and recovery improvements typically follow at 4–6 weeks. Measurable body composition changes generally become apparent at 8–12 weeks, with the most significant improvements occurring between 3–6 months of consistent use.

Can I combine this with Tesamorelin?

Combining multiple GHRH analogs (CJC-1295 and Tesamorelin) requires careful clinical judgment to avoid excessive GH stimulation. Your clinician will assess whether combination therapy is appropriate for your goals and health profile. In some cases, cycling between protocols is preferred over simultaneous use.

Our services